Inactive Instrument

Press Releases Stealth BioTherapeutics Corp

Equities

MITO

US85789A1051

Press Releases

Unlock all the news: Be the first to know and act before the market!

Stealth BioTherapeutics Corp Announces Completion of Merger	17/11/22	AQ
Stealth BioTherapeutics Announces SBT-272 Data Updates and Orphan Drug Designation for the Treatment of Amyotrophic Lateral Sclerosis	02/11/22	AQ
Stealth BioTherapeutics Announces SBT-272 Data Updates and Orphan Drug Designation for the Treatment of Amyotrophic Lateral Sclerosis (ALS)	01/11/22	PR
Stealth BioTherapeutics : Investor Presentation - October 2022	14/10/22	PU
Stealth BioTherapeutics Corp to Hold Extraordinary General Meeting of Shareholders	10/10/22	AQ
Stealth BioTherapeutics Announces Departure of Chief Financial Officer	03/10/22	AQ
Stealth BioTherapeutics Announces Departure of Chief Financial Officer	30/09/22	PR
Stealth BioTherapeutics to Participate in Upcoming Ultra-Rare Disease Events	15/09/22	PR
Stealth BioTherapeutics Corp Enters Definitive Agreement for Going Private Transaction	02/08/22	AQ
Stealth BioTherapeutics : Enters Definitive Agreement for Going Private Transaction - Form 6-K	01/08/22	PU
STEALTH BIOTHERAPEUTICS ANNOUNCES RECEIPT OF NON-COMPLIANCE NOTICE FROM NASDAQ	12/07/22	AQ
STEALTH BIOTHERAPEUTICS : ANNOUNCES RECEIPT OF NON-COMPLIANCE NOTICE FROM NASDAQ - Form 6-K	11/07/22	PU
Stealth BioTherapeutics Corp Announces Receipt of Preliminary Non-Binding Proposal	28/06/22	AQ
Stealth BioTherapeutics Granted Pre-NDA Meeting for Elamipretide as a Potential Treatment for Barth Syndrome	14/06/22	PR
Stealth BioTherapeutics Presents New SBT-272 Data Demonstrating Improvement in Upper Motor Neuron Function in ALS Disease Model at Keystone Neurodegeneration Symposium	08/06/22	PR
Stealth BioTherapeutics Receives Orphan Drug Designation from the European Medicines Agency for Elamipretide for the Treatment of Myopathic Mitochondrial DNA Depletion Syndrome	31/05/22	PR
Stealth BioTherapeutics Announces Data from the Phase 2 ReCLAIM-2 Study of Elamipretide in Geographic Atrophy at the Clinical Trials at the Summit Meeting 2022	23/05/22	PR
Stealth BioTherapeutics Receives Orphan Drug Designation from FDA for Elamipretide for Treatment of Duchenne Muscular Dystrophy	12/05/22	PR
STEALTH BIOTHERAPEUTICS ANNOUNCES DATA FROM RECLAIM-2 PHASE 2 TRIAL OF ELAMIPRETIDE IN GEOGRAPHIC ATROPHY	02/05/22	PR
Stealth BioTherapeutics Announces $8.5 Million in Equity Financings	12/04/22	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Stealth BioTherapeutics Corp

Equities

MITO

US85789A1051

Press Releases

Filters